Alterity Therapeutics concluded the enrollment of its ATH434-201 Phase 2 clinical trial, a significant stride in developing a treatment for multiple system atrophy.

The trial, encompassing 77 participants, is assessing the effectiveness of ATH434 in early-stage MSA patients across various regions.

The study aims to demonstrate target engagement, efficacy, safety, and pharmacokinetics via neuroimaging, protein biomarkers, and wearable sensor evaluations.

Results are anticipated by the fourth quarter of 2024, providing crucial insights for potential ATH434 approval.